What We Know

Lantheus Holdings is weighing a potential sale after receiving a takeover offer from Curium Pharma that values the company at approximately $7 billion, according to Bloomberg News, as reported by Reuters on May 22, 2026.

The two companies have been in active discussions. According to Reuters, people familiar with the matter say a deal could be weeks away.

No final decision has been made. There is no guarantee these talks result in a transaction. Lantheus declined to comment. Curium did not respond to Reuters' request for comment.

Who Are These Companies?

Lantheus Holdings trades on Nasdaq under ticker LNTH. It specializes in radiopharmaceuticals — specifically cancer imaging agents. Its flagship product, Pylarify, is a prostate cancer imaging agent. The company's market capitalization sat at roughly $6.15 billion before the news broke, according to Reuters.

The $7 billion offer represents a meaningful premium to that market cap.

Curium Pharma is a nuclear medicine company backed by private equity firm CapVest Partners. According to Bloomberg, as cited by Reuters, Curium itself was valued at approximately $7 billion last year when CapVest raised funds for a continuation vehicle. This is a well-capitalized firm in the exact same space making a strategic move.

The Stock Reaction

Lantheus shares were trading nearly 2% DOWN in extended trading after the news broke, according to Reuters.

Normally, acquisition rumors send a stock UP. The target company trades at a premium to its current price once a buyout offer surfaces.

The fact that LNTH dropped suggests the market may think either the deal falls apart, the price isn't as attractive as it sounds, or investors who've already ridden a 54.77% gain year-to-date are locking in profits on the news. The stock closed at $103.00 on May 22, per MarketScreener data.

The Leadership Vacuum Problem

Lantheus does not have a permanent CEO right now. Mary Heino is serving as interim CEO. On the company's most recent earnings call, a William Blair analyst noted that Lantheus acknowledged an upward revision to its annual forecast is overdue — but won't happen until a permanent CEO is appointed.

The company is in acquisition talks worth $7 billion, navigating a critical FDA review window, and does not have a permanent chief executive in the seat.

That is a significant governance issue. Boards sometimes use a sale process to sidestep the challenging work of finding permanent leadership. Whether that's happening here remains unknown.

The FDA Factor

Another time-sensitive variable is at play.

In March 2026, the U.S. FDA extended its review of Lantheus' diagnostic imaging kit, LNTH-2501, by three months to allow more time to assess manufacturing-related information. The new decision deadline is June 29, 2026, according to Reuters.

That's weeks away, and Bloomberg reports the potential deal itself could also be weeks away.

Lantheus is simultaneously running a leaderless company, awaiting a pivotal FDA approval, and negotiating a $7 billion sale. The convergence of all three in the same window is either a coincidence or a deliberate acceleration of the sale process ahead of the FDA decision — which would either validate or undermine the company's near-term growth story.

In March, the FDA approved a new formulation of Pylarify aimed at expanding scanning access through increased production capacity. This development likely strengthens what Lantheus offers Curium right now.

The Broader Picture

Radiopharmaceuticals are a hot sector. The convergence of nuclear medicine with precision oncology — using targeted radioactive compounds to both image and destroy cancer cells — is drawing serious capital. Curium acquiring Lantheus would create a major combined player in this space.

This is a strategic consolidation bet that nuclear medicine is the next frontier in cancer treatment. Both companies are playing for that future.

What This Means For Regular People

If you hold LNTH stock, watch the June 29 FDA decision closely. That ruling on LNTH-2501 will either strengthen or weaken Lantheus' negotiating position in these talks.

If you're a patient or a healthcare professional in oncology, a combined Curium-Lantheus entity could mean either expanded access to cutting-edge imaging and treatment tools — or a consolidated pricing power that pushes costs up. Private equity-backed consolidation in pharma has a mixed record on patient outcomes. CapVest backing Curium is a detail worth watching.

Lantheus employees face genuine uncertainty about what happens next.